HARPライブシグナル | Getagraph.comで利益を最大化

買う 107961 min ago

@ $22.46

発行日: 15 2月 2024 @ 02:29

リターン: 2.45%

前回のシグナル: 2月 14 - 23:30

前回のシグナル: 売る

リターン: -0.29 %

Live Chart Being Loaded With Signals

Commentary (9 3月 2024 @ 06:00):

Stats
本日の出来高	6.40M
平均出来高	1.13M
時価総額	865.08M
EPS	$0 ( 2024-03-25 )
次の収益日	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-15.04
ATR14	$0.377 (1.64%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	395 783	Common Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	10 000	8.000% Series A Redeemable Preferred Stock
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	299 430	Common Stock Warrant (Right to Buy)
2024-03-11	New Leaf Biopharma Opportunities Ii, L.p.	Sell	85 750	Common Stock Warrant (Right to Buy)
2024-03-11	Silvernail Lauren P	Sell	5 000	Common Stock

INSIDER POWER
75.66
Last 96 transactions
Buy: 30 137 007 \| Sell: 5 308 481

ボリューム相関

長: 0.48 (neutral)

短: 0.40 (neutral)

Signal:(82.718) Neutral

Harpoon Therapeutics Inc 相関

10 最も正の相関
APOP	0.898
RMRM	0.892
PAIC	0.857
TDAC	0.851
GAINL	0.843
TLGT	0.841
ISNS	0.821
SVAC	0.813
SPRT	0.808

10 最も負の相関
MMAC	-0.899
BOCH	-0.892
NETE	-0.858
AMRB	-0.844
SHSP	-0.811
DSPG	-0.808

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Harpoon Therapeutics Inc 相関 - 通貨/商品

-0.16
( neutral )

0.64
( weak )

0.52
( weak )

0.07
( neutral )

0.58
( weak )

0.29
( neutral )

Harpoon Therapeutics Inc 財務諸表

Annual	2022
収益:	$31.92M
総利益:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2022
収益:	$31.92M
総利益:	$28.82M (90.30 %)
EPS:	$-20.24

FY	2021
収益:	$23.65M
総利益:	$23.65M (100.00 %)
EPS:	$-3.62

FY	2020
収益:	$17.44M
総利益:	$17.44M (100.00 %)
EPS:	$-1.990

Financial Reports:

No articles found.

Harpoon Therapeutics Inc

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.